Investigation of the Response Relationship of NN5401 in Type 1 Diabetics
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the
pharmacodynamic dose-response relationship of NN5401 (insulin degludec/insulin aspart) at
three therapeutically relevant doses in subjects with type 1 diabetes.
The trial is designed as a four period, incomplete block cross-over trial where the trial
participant will be randomised to a treatment sequence by which the subject will receive two
matched dose levels of NN5401 and biphasic insulin aspart, respectively.